Functional differences between direct and indirect striatal output pathways in Huntington's disease

Journal of Huntington's Disease

Volumn 1, Issue 1, 2012, Pages 17-25

  Galvan, Laurie ^a   André, Véronique M ^a   Wang, Elizabeth A ^a   Cepeda, Carlos ^a   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dopamine modulation; excitation; Huntington's disease; inhibition; Medium sized spiny neurons

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DYNORPHIN; ENDOCANNABINOID; ENHANCED GREEN FLUORESCENT PROTEIN; GLUTAMIC ACID; HISTAMINE; RHODOPSIN; SUBSTANCE P; TETRABENAZINE;

CELL NUCLEUS; CELL STRUCTURE; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; EXCITATORY POSTSYNAPTIC POTENTIAL; FOOD AND DRUG ADMINISTRATION; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; MEDIUM SIZED SPINY NEURON; NERVE CELL; NERVE CELL NETWORK; NEUROMODULATION; NONHUMAN; OPTOGENETICS; PATHOGENESIS; PRIORITY JOURNAL; PYRAMIDAL TRACT; REVIEW; SIGNAL TRANSDUCTION; STEREOTYPY; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS RETICULATA; SYNAPTIC TRANSMISSION; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONS; SYNAPTIC TRANSMISSION;

EID: 84904898590     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-2012-120009     Document Type: Review

References (82)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-83.
2. Bird ED. Chemical pathology of Huntington's disease. Annu Rev Pharmacol Toxicol. 1980;20:533-51.
3. Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother. 2007;8(2):141-53. (Pubitemid 46206617)
4. Heinsen H, Rub U, Gangnus D, Jungkunz G, Bauer M, Ulmar G, et al. Nerve cell loss in the thalamic centromedianparafascicular complex in patients with Huntington's disease. Acta Neuropathol. 1996;91(2):161-68. (Pubitemid 26021403)
5. Kassubek J, Gaus W, Landwehrmeyer GB. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2004;62(3):523-4; author reply 4. (Pubitemid 38200883)
6. Kremer HP, Roos RA, Dingjan G, Marani E, BotsGT. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol. 1990;49(4):371-82. (Pubitemid 20207798)
7. Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM, et al. Orexin loss in Huntington's disease. Hum Mol Genet. 2005;14(1):39-47. (Pubitemid 40123461)
8. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985; 44(6):559-77. (Pubitemid 16196286)
9. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-84. (Pubitemid 28237321)
10. Ferrer I, Kulisewsky J, González G, Escartín A, Chivite A, Casas R. Parvalbumin-immunoreactive neurons in the cerebral cortex and striatum in Huntington's disease. Neurodegeneration. 1994;3:169-73.
11. Massouh M, Wallman MJ, Pourcher E, Parent A. The fate of the large striatal interneurons expressing calretinin in Huntington's disease. Neurosci Res. 2008;62(4):216-24.
12. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21(9):1317-25. (Pubitemid 44613279)
13. Kita H, Kitai ST. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res. 1988;447(2):346-52.
14. Wilson CJ. Basal Ganglia. In: Shepherd GW, ed. The synaptic organization of the brain. Oxford: Oxford University Press, 1990;279-316.
15. Bolam JP, Hanley JJ, Booth PA, Bevan MD. Synaptic organisation of the basal ganglia. J Anat. 2000;196(Pt 4):527-42. (Pubitemid 30458775)
16. Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 2004;27(9):520-7. (Pubitemid 39149820)
17. Kemp JM. The site of termination of afferent fibres on the neurones of the caudate nucleus. J Physiol. 1970;210(1):17P-8P.
18. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 1990;13(7):244-54. (Pubitemid 20193453)
19. Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30(10):545-53. (Pubitemid 47513239)
20. Tepper JM, Wilson CJ, Koos T. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res Rev. 2008;58(2):272-81.
21. Cicchetti F, Prensa L, Wu Y, Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev. 2000;34(1-2):80-101.
22. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr. , Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987;411(1):162-6. (Pubitemid 17084782)
23. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr. , Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 1985;230(4725):561-3. (Pubitemid 16169813)
24. Kawaguchi Y, Wilson CJ, Emson PC. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci. 1990;10(10):3421-38.
25. Andre VM, Cepeda C, Cummings DM, Jocoy EL, Fisher YE, William Yang X, et al. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci. 2010;31(1):14-28.
26. Shuen JA, Chen M, Gloss B, Calakos N. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci. 2008;28(11):2681-5. (Pubitemid 351398859)
27. Surmeier DJ, Song WJ, Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci. 1996;16(20):6579-91. (Pubitemid 26337379)
28. Gerfen CR, Engber TM,Mahan LC, Susel Z, Chase TN, Monsma FJ Jr. , et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250(4986):1429-32. (Pubitemid 120031867)
29. Haber SN, Nauta WJ. Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry. Neuroscience. 1983;9(2):245-60. (Pubitemid 13077591)
30. Vincent S, Hokfelt T, Christensson I, Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur J Pharmacol. 1982;85(2):251-2. (Pubitemid 13223241)
31. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-75. (Pubitemid 19238787)
32. Steiner H, Gerfen CR. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience. 1999;88(3):795-810. (Pubitemid 28518258)
33. Albin RL, Reiner A, Anderson KD, Dure LSt, Handelin B, Balfour R, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol. 1992;31(4):425-30.
34. Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, et al. Decrease in striatal enkephalin mRNAin mouse models of Huntington's disease. Exp Neurol. 2000;162(2):328-42. (Pubitemid 30217728)
35. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988;85(15):5733-7.
36. Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol. 1995;38(6):852-61. (Pubitemid 26004067)
37. Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience. 1995;64(2):397-404.
38. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington's disease: A quantitative immunohistochemical study. J Chem Neuroanat. 2004;27(3):143-64. (Pubitemid 38739355)
39. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol. 1990;27(4):357-65. (Pubitemid 20132050)
40. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol. 1995;54(1):105-20.
41. Spektor BS, Miller DW, Hollingsworth ZR, Kaneko YA, Solano SM, Johnson JM, et al. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res Mol Brain Res. 2002;102(1-2):118-28. (Pubitemid 34607750)
42. Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington's disease: Time-dependent alterations in synaptic and receptor function. Neuroscience. 2011;198:252-73.
43. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010;65(2):178-90.
44. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15(12):1407-13.
45. Reiner A, Jiao Y, Del Mar N, Laverghetta AV, Lei WL. Differential morphology of pyramidal tract-type and intratelencephalically projecting-type corticostriatal neurons and their intrastriatal terminals in rats. J Comp Neurol. 2003;457(4):420-40. (Pubitemid 36255337)
46. Lei W, Jiao Y, Del Mar N, Reiner A. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci. 2004;24(38):8289-99. (Pubitemid 39280808)
47. Ballion B, Mallet N, Bezard E, Lanciego JL, Gonon F. Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism. Eur J Neurosci. 2008;27(9):2313-21. (Pubitemid 351590902)
48. Cepeda C, Andre VM, Yamazaki I, Wu N, Kleiman-Weiner M, Levine MS. Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal mediumsized spiny neurons. Eur J Neurosci. 2008;27(3):671-82. (Pubitemid 351239295)
49. Gertler TS, Chan CS, Surmeier DJ. Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci. 2008;28(43):10814-24.
50. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445(7128):643-7. (Pubitemid 46232883)
51. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28(24):6182-95.
52. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain. 2009;132(Pt 4): 919-32.
53. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12(13):1555-67. (Pubitemid 36857303)
54. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in theYAC128 mouse model of Huntington disease. Hum Mol Genet. 2005;14(24):3823-35. (Pubitemid 43020084)
55. Andre VM, Cepeda C, Fisher YE, Huynh M, Bardakjian N, Singh S, et al. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci. 2011;31(4):1170-82.
56. Andre VM, Fisher YE, Levine MS. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front Syst Neurosci. 2011; 5:46.
57. Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci. 2009;29(8):2414-27.
58. Cepeda C, Buchwald NA, Levine MS. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A. 1993;90(20):9576-80. (Pubitemid 23315828)
59. Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS. Dopaminergic modulation ofNMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol. 1998;79(1):82-94. (Pubitemid 28133801)
60. Dumartin B, Jaber M, Gonon F, Caron MG, Giros B, Bloch B. Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proc Natl Acad Sci U S A. 2000;97(4):1879-84. (Pubitemid 30118537)
61. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379(6566):606-12. (Pubitemid 26052818)
62. Wu N, Cepeda C, Zhuang X, Levine MS. Altered corticostriatal neurotransmission and modulation in dopamine transporter knock-down mice. J Neurophysiol. 2007;98(1):423-32. (Pubitemid 47084832)
63. Huntington, Study, Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366-72.
64. Pettibone DJ, Pflueger AB, Totaro JA, Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol. 1984;102(3-4):431-6. (Pubitemid 14064082)
65. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. 2009;(3):CD006456.
66. Tang TS, Chen X, Liu J, Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci. 2007;27(30):7899-910. (Pubitemid 47173323)
67. Richfield EK, Penney JB, Young AB. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience. 1989;30(3):767-77. (Pubitemid 19197155)
68. Rice ME, Cragg SJ. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev. 2008;58(2):303-13.
69. Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, et al. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience. 2007;147(2):354-72. (Pubitemid 46907444)
70. Gittis AH, Nelson AB, Thwin MT, Palop JJ, Kreitzer AC. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. J Neurosci. 2010;30(6):2223-34.
71. Boyden ES. A history of optogenetics: the development of tools for controlling brain circuits with light. F1000 Biol Rep. 2011;3:11.
72. Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. Neuron. 2011;71(1):9-34.
73. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science. 2009;324(5925):354-9.
74. Kravitz AV, Kreitzer AC. Optogenetic manipulation of neural circuitry in vivo. Curr Opin Neurobiol. 2011;21(3):433-9.
75. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003;425(6961):917-25. (Pubitemid 37376918)
76. Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622-6.
77. Ellender TJ, Huerta-Ocampo I, Deisseroth K, Capogna M, Bolam JP. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. J Neurosci. 2011;31(43):15340-51.
78. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998;121(Pt 7):1329-41. (Pubitemid 28327409)
79. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-80.
80. Goodchild RE, Court JA, Hobson I, Piggott MA, Perry RH, Ince P, et al. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur J Neurosci. 1999;11(2):449-56. (Pubitemid 29050447)
81. Martinez-Mir MI, Pollard H, Moreau J, Traiffort E, Ruat M, Schwartz JC, et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse. 1993;15(3):209-20. (Pubitemid 23339513)
82. vanWamelen DJ, Shan L, Aziz NA, Anink JJ, Bao AM, Roos RA, et al. Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol. 2011;21(4):419-27.